Search Within

Paul Hamlin

Formats
  1. Meeting Abstract (183)
  2. Journal Article (101)
  3. Research Letter (7)
  4. Correspondence (1)
  5. Review (1)
Groups
  1. Center for Hematologic Malignancies (293)
  2. Department of Medicine (293)
  3. Hematologic Malignancies, Division of (293)
  4. Lymphoma (293)
  5. Population Sciences Research Program (152)
  6. Survivorship Research (145)

More Groups

People
  1. Andrew Zelenetz (186)
  2. Ariela Noy (144)
  3. Steven Horwitz (139)
  4. Maria Palomba (125)
  5. David Straus (122)
  6. Alison Moskowitz (119)

More People

Years
  1. 2025 (6)
  2. 2024 (24)
  3. 2023 (21)
  4. 2022 (12)
  5. 2021 (17)
  6. 2020 (13)

More Years

Publications
  1. Blood (125)
  2. Journal of Clinical Oncology (38)
  3. Hematological Oncology (15)
  4. Annals of Oncology (12)
  5. British Journal of Haematology (12)
  6. Haematologica (10)

More Publications

Publishers
  1. American Society of Hematology (134)
  2. American Society of Clinical Oncology (40)
  3. Wiley Blackwell (19)
  4. Elsevier Inc. (16)
  5. Oxford University Press (13)
  6. John Wiley & Sons (12)

More Publishers

Results (293)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Development of a geriatric service in a cancer center: Lessons learned
    Journal Article

    Korc-Grodzicki, B.; Tew, W.; Hurria, A.; Yulico, H.; Lichtman, S.; Hamlin, P.; Bosl, G.
    Journal of Oncology Practice (2017)

    Fulltext@MSK | Save
  • Cerdulatinib (PRT062070): A dual SYK/JAK inhibitor in patients with relapsed/refractory b-cell malignancies - Pharmacokinetic and pharmacodynamic outcomes with twice-daily (BID) vs once-daily (QD) dosing
    Meeting Abstract

    Hamlin, P. A.; Flinn, I.; Wagner-Johnston, N.; Burger, J.; Michelson, G.; Pandey, A.; Birrell, M.; Coffey, G.; Leeds, J.; Sabalvaro-Torres, A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A Phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M.; Lynch, P.; Scheuerman, M.; Kumar, A.; Gerecitano, J. F.; Zelenetz, A. D.; Hamlin, P. A. Jr; Noy, A.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Outcome of initial observation in mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Ying, Z.; Alperovich, A.; Dogan, A.; Hamlin, P. A. Jr; Moskowitz, C. H.; Portlock, C. S.; Zelenetz, A. D.; Zhang, Z.; Woo, K. M.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Outcomes of follicular lymphoma patients by dynamic FLIPI at diagnosis and initial treatment in the post-rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Benchmark of progression free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Sequential brentuximab vedotin and adriamycin, vinblastine, and dacarbazine for older patients with untreated Hodgkin lymphoma: Findings from a phase II Window study
    Meeting Abstract

    Evens, A. M.; Hamlin, P. A.; Nabhan, C.; Advani, R.; Fanale, M.; Petrich, A.; Smith, S.; Bociek, G.; Winter, J.; Gordon, L. I.
    Haematologica (2016)

    Fulltext@MSK | Save
  • PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Schòˆder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Obinutuzumab plus bendamustine in rituximab-refractory indolent lymphoma
    Journal Article

    Hamlin, P. A.
    Lancet Oncology (2016)

    Fulltext@MSK | Save
  • Allogeneic hematopoietic cell transplantation as curative therapy for patients with non-Hodgkin lymphoma: Increasingly successful application to older patients
    Journal Article

    Fenske, T. S.; Hamadani, M.; Cohen, J. B.; Costa, L. J.; Kahl, B. S.; Evens, A. M.; Hamlin, P. A.; Lazarus, H. M.; Petersdorf, E.; Bredeson, C.
    Biology of Blood and Marrow Transplantation (2016)

    Fulltext@MSK | Save